12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BI-505: Phase II started

BioInvent began an open-label, European Phase II trial to evaluate 10 mg/kg BI-505 given every other week in up to 10 patients with asymptomatic MM. The...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >